VINCERX PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6824 USD | -1.19% |
|
-10.21% | -42.17% |
| 26/04 | Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday | MT |
| 26/04 | Vincerx Pharma Prices Public Offering of Shares, Warrants | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 292.4 | 214.2 | 21.61 | 25.23 | 20.15 | - | - |
| Enterprise Value (EV) 1 | 292.4 | 214.2 | -30.85 | 25.23 | 20.15 | 20.15 | 20.15 |
| P/E ratio | - | - | -0.33 x | -0.62 x | -0.54 x | -0.7 x | -0.66 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 23.2 x |
| EV / Revenue | - | - | - | - | - | - | 23.2 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | -128 x | -6.36 x | -0.36 x | - | -0.75 x | -0.49 x | -0.35 x |
| FCF Yield | -0.78% | -15.7% | -276% | - | -134% | -203% | -288% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,984 | 21,021 | 21,190 | 21,381 | 29,534 | - | - |
| Reference price 2 | 20.91 | 10.19 | 1.020 | 1.180 | 0.6824 | 0.6824 | 0.6824 |
| Announcement Date | 22/03/21 | 29/03/22 | 28/03/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 0.87 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -0.0448 | -10.71 | -62.66 | -71.1 | -42.61 | -28.73 | -35.4 | -56 |
| Operating Margin | - | - | - | - | - | - | - | -6,436.78% |
| Earnings before Tax (EBT) 1 | - | - | - | -65.37 | -40.16 | -28.92 | -34.8 | -54 |
| Net income 1 | - | - | - | -65.37 | -40.16 | -28.92 | -34.8 | -54 |
| Net margin | - | - | - | - | - | - | - | -6,206.9% |
| EPS 2 | -0.0100 | - | - | -3.110 | -1.890 | -1.260 | -0.9733 | -1.030 |
| Free Cash Flow 1 | - | -2.28 | -33.66 | -59.6 | - | -27 | -41 | -58 |
| FCF margin | - | - | - | - | - | - | - | -6,666.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 08/10/20 | 22/03/21 | 29/03/22 | 28/03/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -17.71 | -21.63 | -19.62 | -15.59 | -15.42 | -15.1 | -11.66 | -10.32 | -5.533 | -7.478 | -6.863 | -6.746 | -6.99 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | -16.88 | -13.64 | -14.34 | -11.15 | -9.715 | -4.95 | -12.43 | -6.413 | -6.311 | -6.51 |
| Net income 1 | - | - | - | -16.88 | -13.64 | -14.34 | -11.15 | -9.715 | -4.95 | -12.43 | -6.413 | -6.311 | -6.51 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | -0.8000 | -0.6500 | -0.6800 | -0.5200 | -0.4600 | -0.2300 | -0.5800 | -0.2400 | -0.2400 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 29/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 28/03/23 | 11/05/23 | 07/08/23 | 14/11/23 | 29/03/24 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | 52.5 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.28 | -33.7 | -59.6 | - | -27 | -41 | -58 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 0.26 | - | - | - | 1 | 1 |
| Capex / Sales | - | - | - | - | - | - | 114.94% |
| Announcement Date | 22/03/21 | 29/03/22 | 28/03/23 | 29/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6824
USD
Average target price
9
USD
Spread / Average Target
+1,218.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.17% | 2.04Cr | |
| +9.58% | 11TCr | |
| +12.41% | 11TCr | |
| -2.59% | 2.2TCr | |
| -12.38% | 2.19TCr | |
| -5.29% | 1.92TCr | |
| -3.35% | 1.81TCr | |
| -38.57% | 1.77TCr | |
| +7.51% | 1.43TCr | |
| +35.67% | 1.24TCr |
- Stock Market
- Equities
- VINC Stock
- Financials Vincerx Pharma, Inc.